Delcath Systems (DCTH) Stock: September Could Be A Huge Month

Delcath Systems, Inc. (NASDAQ: DCTH) has been an incredibly interesting stock to watch as of late. We’ve seen ups, we’ve seen downs, and we’ve seen the debates. Nonetheless, there are several very good reasons to hang on here, and one of them is that September could be an incredibly strong month. Before we get into why, we’d like to give a big thank you to our friends at Trade Ideas for keeping the stock on our radar. At the moment (8:12), DCTH is trading at $0.16 per share after a gain of $0.01 per share (5.41%) thus far today.

Why September Could Be A Very Big Month For DCTH

As mentioned above, Delcath Systems has seen its ups and downs recently, but some big and overwhelmingly positive movement could be coming down the line – and very soon. That’s because a key clinical trial is scheduled to be completed just next month.

In a document found on, there are published dates surrounding a study titled “Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients with Unresectable HCC”. While the study was first submitted on March 23, 2015, it should be coming to an end relatively soon. In fact, the documentation linked to above says that DCTH expects final data collection for the primary outcome measure to happen this month. On top of that, study completion is expected in September.

Considering previous data surrounding Chemosat by DCTH, it only makes sense that data from this trial is likely to be positive. While the company continues to save lives in Europe, an approval in the United States would be a massive win for Delcath Systems, and the data release that should be coming soon will bring the company one step closer to that goal.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on DCTH. In particular, we’re interested in following the company’s ongoing work to bring Chemosat to patients in need in the United States. Also, we haven’t seen an official release from the company with regard to the potential stock split. While there are some reports suggesting that investors voted against it, we’re awaiting official word from the company. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment